APSMNF
APSMNF is in Phase 3 for androgenetic alopecia, developed by Apsen Farmacêutica.
An undisclosed Apsen candidate, APSMNF, registered for a Phase 3 in men against the company's own marketed minoxidil solution, Eniagor.
- Developed by
- Apsen Farmacêutica
- Current phase
- Phase 3
- Mechanism
- Undisclosed
- Indications
- Androgenetic alopecia
- Also known as
- APSMNF, APSMNF 1, APSMNF 2
- Last public activity
- September 2026
- Copy last reviewed
- September 2026
- Record confidence
- Low
Large confirmatory trials. The last step before filing.
The sponsor has not said how it is supposed to work.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
One of several Brazilian registrational programmes in this register. The study, due to start in October 2026 at a single site in Campinas with 336 men, runs two experimental arms of APSMNF against Eniagor, Apsen's marketed 5% minoxidil scalp solution, which makes it a head-to-head against the standard rather than placebo. The registry does not say what APSMNF is or how the two arms differ.
Development history
- Phase 3
First Phase 3 trial on record: NCT07516561 — Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Apsen Farmaceutica S.A. · n=336 · October 2026
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Eniagor in men with androgenetic alopecia — ClinicalTrials.gov
- Eniagor (minoxidil 5% scalp solution), Apsen product page — Company release
Cite this page
Hair Pipeline, "APSMNF — development record", hairpipeline.com/pipeline/eniagor